Healthcare utilization and costs for patients initiating Dabigatran or Warfarin. - Wikidata - awgldk - TriplyDB

Healthcare utilization and costs for patients initiating Dabigatran or Warfarin.

Healthcare utilization and costs for patients initiating Dabigatran or Warfarin.

http://www.wikidata.org/entity/Q33823354

about

Healthcare utilization and costs for patients initiating Dabigatran or Warfarin.

http://www.wikidata.org/entity/Q33823354

description

2017 nî lūn-bûn

@nan

2017 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2017 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

name

Healthcare utilization and costs for patients initiating Dabigatran or Warfarin.

@ast

Healthcare utilization and costs for patients initiating Dabigatran or Warfarin.

@en

type

label

Healthcare utilization and costs for patients initiating Dabigatran or Warfarin.

@ast

Healthcare utilization and costs for patients initiating Dabigatran or Warfarin.

@en

prefLabel

Healthcare utilization and costs for patients initiating Dabigatran or Warfarin.

@ast

Healthcare utilization and costs for patients initiating Dabigatran or Warfarin.

@en

P1433

Q33823354-F6BA6AD7-2357-4F9A-A913-0038210BEB52

P1476

Q33823354-13A97907-2905-4995-8F42-04E0ABCDC980

P2093

Q33823354-086F2A14-77C4-401D-A1AF-BE1AF5AC2F9D

Q33823354-17D8B7DB-5D95-471F-9178-E2BDEFCF4A0B

Q33823354-18139DDA-C804-4419-A061-85C2FEDE6634

Q33823354-26547DE8-6F47-4372-AB85-97DE87559DE5

Q33823354-2C79DE64-185A-4527-B5EC-26FDB71C3A1B

Q33823354-3978D07D-202B-458F-A38D-E00557D273F4

Q33823354-5DECCE5A-233E-4D23-8372-0559FDCB45FE

Q33823354-8AA6C218-0383-4DDF-9B1E-DBE019C2CB69

Q33823354-C6FDADDB-7860-43E3-B39F-6BFD36F5290A

Q33823354-F1A5701E-751A-4A07-8EB5-66CF0B567CD0

P2860

Q33823354-186D4988-1BFE-4666-95DE-FA79D65379BE

Q33823354-21C3439A-53EE-42FB-8731-B24AA43B9725

Q33823354-29F94AA5-2535-4AED-AD51-50F88BA62EFF

Q33823354-34044AAD-9BBC-41DB-8DF5-84302C493224

Q33823354-3EDBC8BC-AEF6-40C1-902B-6FB549CB094D

Q33823354-4B7CD5EA-884C-4186-B384-122B9B69A153

Q33823354-4BB15215-E877-4779-8155-E028C22CA543

Q33823354-57139518-0CED-4FFB-B81E-728055C722B5

Q33823354-580FEE1D-389C-41C1-B968-914530B25983

Q33823354-5A101538-4E6A-4CA3-ADFA-AB971015196F

P2888

Q33823354-A66C6EB3-37C5-4406-A043-EA2A15AC4C83

P304

Q33823354-51F1342E-9EA7-4A27-814F-B6DDF5CB619C

P31

Q33823354-CB7DBAB6-581F-4BEB-8FC1-31AD5E73DDAA

P356

Q33823354-1848F9D5-016D-4795-907D-535D420098B1

P433

Q33823354-3CEB24BB-6134-48AC-AF8D-6B9CC55EBDBA

P478

Q33823354-3D6747F4-D9D3-4856-9A73-48E2FDD5F709

P577

Q33823354-4B191337-F079-418B-A169-3B595F16F906

P6179

Q33823354-A0C5512A-2304-4790-B770-7AFE8FED4142

P698

Q33823354-3EC50187-164B-4112-B766-EDCE8C25CEB6

P932

Q33823354-85FFBE51-C40E-49DF-A9B7-FED849CF80C4

P356

S12955-017-0705-X

P1433

Health and Quality of Life Outcomes

P1476

Healthcare utilization and costs for patients initiating Dabigatran or Warfarin.

@en

P2093

Chad Moretz

http://www.w3.org/2001/XMLSchema#string

Cheng Wang

http://www.w3.org/2001/XMLSchema#string

George Andrews

http://www.w3.org/2001/XMLSchema#string

Mary E Costantino

http://www.w3.org/2001/XMLSchema#string

Pranav K Gandhi

http://www.w3.org/2001/XMLSchema#string

Richard Sheer

http://www.w3.org/2001/XMLSchema#string

Sameer R Ghate

http://www.w3.org/2001/XMLSchema#string

Shannon L Reynolds

http://www.w3.org/2001/XMLSchema#string

Srinivas Annavarapu

http://www.w3.org/2001/XMLSchema#string

Stephen Sander

http://www.w3.org/2001/XMLSchema#string

P2860

Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation

Dabigatran versus warfarin in patients with atrial fibrillation

2011 ACCF/AHA/HRS Focused Updates Incorporated Into the ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation

Validation of Clinical Classification Schemes for Predicting Stroke

Heart disease and stroke statistics--2012 update: a report from the American Heart Association

Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study

Atrial fibrillation as an independent risk factor for stroke: the Framingham Study

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation

Apixaban versus warfarin in patients with atrial fibrillation

Comorbidity measures for use with administrative data.

P2888

s12955-017-0705-x

P304

128

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S12955-017-0705-X

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P577

2017-06-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1086107274

http://www.w3.org/2001/XMLSchema#string

P698

28637460

http://www.w3.org/2001/XMLSchema#string

P932

5480105

http://www.w3.org/2001/XMLSchema#string